Regeneron's baloncibart cuts standing heart rate by 11.4 bpm in Phase 2 POTS trial
ahandvanish · x · 2026-11-14
Regeneron's Phase 2 trial in 82 POTS patients found that a single dose of baloncibart reduced standing heart rate by 11.4 bpm versus placebo and improved symptoms. The antibody blocks NPR1, with biomarkers suggesting increased blood volume as the mechanism.
More from Research
- Curing cancer is the least compelling case for AGI, researchers argue — anshulkundaje · 2026-11-14
- AI cracks Gödel's 1,009-page notebooks, revealing hundreds of unknown theorems — nordicinst · 2026-11-14
- Would galaxy-scale intelligence even have Navier–Stokes? Twitter debates whether intelligence is compression — rickasaurus · 2026-11-14
- Salesforce's SFR-AutoR&D agent boosts retrieval score 6.13 points — at 3x wider vectors — krishnan · 2026-11-14
- AI 'slop' is a social judgement, argue authors in Nature Human Behaviour paper — BrihiJ · 2026-11-14
- 200+ models trained from scratch: only one multimodal encoding choice matters — sainingxie · 2026-11-14